Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.53 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | CDC25A | P30304 | 1/20 | 0.53 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.53 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | DGKA | P23743 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2638014 | 1.00 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL3983857 | 1.00 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL31432721 | 1.00 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL1768918 | 1.00 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL22721397 | 1.00 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL1341976 | 1.00 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL6666152 | 0.98 | FABP3 (0.52) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL617162 | 0.92 | ALDH1A1 (0.53) | FABP3SMN1; SMN2NR5A2NR5A1 | |
| SCHEMBL1643923 | 0.87 | FABP3 (0.62) | FABP3SMN1; SMN2NR5A2NR5A1LMNA | |
| SCHEMBL5475892 | 0.87 | FABP3 (0.62) | FABP3SMN1; SMN2NR5A2NR5A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026050790-A1 | DISSOLVING MICRONEEDLES ENCAPSULATING ALLERGEN-LOADED LIPOSOMES FOR ALLERGEN IMMUNOTHERAPY | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2026-03-12 | — | — | WO | disclosed |
| EP-4694884-A2 | METHODS OF USE OF A LIPOSOMAL COMPOSITION COMPRISING AN ATR INHIBITOR | Jazz Pharmaceuticals Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4694883-A2 | COMBINATIONS COMPRISING AN ATR INHIBITOR AND A PARP INHIBITOR AND METHODS OF USE THEREOF | Jazz Pharmaceuticals Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4636090-A1 | UTR FOR IMPROVING TRANSLATION EFFICIENCY AND/OR STABILITY OF RNA MOLECULE AND USE THEREOF | Shenzhen Shenxin Biotechnology Co., Ltd. (CN) | 2025-10-22 | — | — | EP | disclosed |
| WO-2025047645-A1 | METHOD FOR SIMULTANEOUS DETECTION OF BIOMOLECULES USING TEMPERATURE-RESPONSIVE FLUORESCENT PARTICLES | 学校法人早稲田大学 | 2025-03-06 | — | — | WO | disclosed |
| WO-2025019344-A2 | COMBINATIONS COMPRISING AN ATR INHIBITOR AND A PARP INHIBITOR AND METHODS OF USE THEREOF | Jazz Pharmaceuticals, Inc. (US) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025019346-A2 | METHODS OF USE OF A LIPOSOMAL COMPOSITION COMPRISING AN ATR INHIBITOR | CELATOR PHARMACEUTICALS, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| CN-114573574-A | Crystalline form of a compound | 爱杜西亚药品有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20180369336-A1 | B CELL-BASED CANCER IMMUNOTHERAPY | BOSTON MEDICAL CENTER CORPORATION (US) | 2018-12-27 | — | — | US | disclosed |
| EP-1906924-B1 | BONE MARROW-DIRECTING DRUG DELIVERY MATERIALS AND THEIR APPLICATIONS | UNIV WASEDA (JP) | 2018-05-02 | — | — | EP | disclosed |
| EP-1146911-A2 | NOVEL METHODS OF IMAGING AND TREATMENT WITH TARGETED COMPOSITIONS | IMARX PHARMACEUTICAL CORP. (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6231834-B1 | ADMINISTRATION TO A PATIENT OF A CONTRAST AGENT COMPRISING AN AQUEOUS CARRIER, A LIPID, PROTEIN OR POLYMERA AND SCANNING THE PATIENT USING ULTRASOUND IMAGING TO OBTAIN VISIBLE IMAGE OF THE REGION BY TAKING TWO IMAGES | IMARX PHARMACEUTICAL CORP. | 2001-05-15 | — | — | US | disclosed |
| US-6139819-A | COMPRISING LIPID, PROTEIN, POLYMER AND/OR SURFACTANT, AND A GAS, IN COMBINATION WITH A TARGETING LIGAND; TARGETING LIGAND TARGETS COAGULA, INCLUDING EMBOLI AND/OR THROMBI, PARTICULARLY IN PATIENTS SUFFERING FROM ARRHYTHMIC DISORDER | IMARX PHARMACEUTICAL CORP. (US) | 2000-10-31 | — | — | US | disclosed |
| WO-2000045856-A2 | NOVEL METHODS OF IMAGING AND TREATMENT WITH TARGETED COMPOSITIONS | IMARX PHARMACEUTICAL CORP. (US) | 2000-08-10 | — | — | WO | disclosed |
| EP-0831932-A4 | NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE | IMARX PHARMACEUTICAL CORP (US) | 2000-01-12 | — | — | EP | disclosed |
| EP-0959908-A1 | NOVEL TARGETED CONTRAST AGENTS FOR DIAGNOSTIC AND THERAPEUTIC USE | IMARX PHARMACEUTICAL CORP. (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1999013919-A1 | NOVEL TARGETED CONTRAST AGENTS FOR DIAGNOSTIC AND THERAPEUTIC USE | IMARX PHARMACEUTICAL CORP. (US) | 1999-03-25 | — | — | WO | disclosed |
| CN-1208603-A | Paraffin micro-dispersing composite and hair conditioning prepn. and finishing agent | SHISEIDO CO LTD (JP) | 1999-02-24 | — | — | CN | disclosed |
| EP-0831932-A1 | NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE | IMARX PHARMACEUTICAL CORP. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040285-A1 | NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE | IMARX PHARMACEUTICAL CORP. (US) | 1996-12-19 | — | — | WO | disclosed |